| Bioactivity | Oxybutynin is an anticholinergic agent, which inhibits vascular Kv channels in a concentration-dependent manner, with an IC50 of 11.51 μM[1]. | ||||||||||||
| Invitro | Oxybutynin (0.1, 0.3, 1, 3, 10, 30, 100 μM; 200 ms) inhibits vascular Kv channels in a concentration-dependent manner independent of anticholinergic effect in coronary arterial smooth muscle cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | Oxybutynin (27.2 mg/kg; p.o.; single) exhibits significant binding of mouse brain muscarinic receptors that about a 2-fold increase in Kd values for specific [3H]N-methylscopolamine binding 0.5 and 2 h later[2]. Animal Model: | ||||||||||||
| Name | Oxybutynin | ||||||||||||
| CAS | 5633-20-5 | ||||||||||||
| Formula | C22H31NO3 | ||||||||||||
| Molar Mass | 357.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Li H, et al. The anticholinergic drug oxybutynin inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):1030-1036. [2]. Oki T, et al. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. |